With characteristics of the GLP-1 analogue, exenatide, added to CSII in hospitalization, we could evaluate the real response of the GLP-1 analogue in patients with poorly controlled type 2 diabetes mellitus by optimizing the baseline glucose. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.